Anti-inflammatory effect of topical administration of tofacitinib on corneal inflammation

Experimental Eye Research

Volumn 145, Issue , 2016, Pages 110-117

  Sakimoto, Tohru ^a   Ishimori, Akiko ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Alkali burn; Corneal inflammation; Janus kinase inhibitor; Small molecule drug; Tofacitinib

Indexed keywords

CXCL9 CHEMOKINE; DIMETHYL SULFOXIDE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON; GELATINASE B; JANUS KINASE; MONOCYTE CHEMOTACTIC PROTEIN 3; OCULAR ANTIINFLAMMATORY AGENT; SECONDARY LYMPHOID TISSUE CHEMOKINE; STAT1 PROTEIN; TOFACITINIB; JANUS KINASE 3; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CAUSTIC BURN; CONTROLLED STUDY; CORNEA DISEASE; CORNEA STROMA; CORNEAL INFLAMMATION; DOWN REGULATION; DRUG EFFECT; DRUG SCREENING; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; LASER CAPTURE MICRODISSECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL CULTURE; COMPLICATION; CORNEA; CORNEAL NEOVASCULARIZATION; DISEASE MODEL; DRUG EFFECTS; KERATITIS; PATHOLOGY; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; CELLS, CULTURED; CORNEA; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; JANUS KINASE 3; KERATITIS; MALE; MICE; MICE, INBRED BALB C; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES;

EID: 84949844277     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2015.12.005     Document Type: Article

References (27)

1. Al-Khatib K., Williams B.R., Silverman R.H., Halford W., Carr D.J. Distinctive roles for 2',5'-oligoadenylate synthetases and double-stranded RNA-dependent protein kinase R in the in vivo antiviral effect of an adenoviral vector expressing murine IFN-beta. J. Immunol. 2004, 172(9):5638-5647.
2. Balagué C., Pont M., Prats N., Godessart N. Profiling of dihydroorotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant-induced arthritis model: a translational study. Br. J. Pharmacol. 2012, 166(4):1320-1332.
3. Boy M.G., Wang C., Wilkinson B.E., Chow V.F., Clucas A.T., Krueger J.G., Gaweco A.S., Zwillich S.H., Changelian P.S., Chan G. Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. J. Invest. Dermatol 2009, 129(9):2299-2302.
4. Clark J.D., Flanagan M.E., Telliez J.B. Discovery and development of janus kinase (JAK) inhibitors for inflammatory diseases. J. Med. Chem. 2014, 57(12):5023-5038.
5. de Koning H.D., Rodijk-Olthuis D., van Vlijmen-Willems I.M., Joosten L.A., Netea M.G., Schalkwijk J., Zeeuwen P.L. A comprehensive analysis of pattern recognition receptors in normal and inflamed human epidermis: upregulation of dectin-1 in psoriasis. J. Invest. Dermatol 2010, 130(11):2611-2620.
6. Fleischmann R., Kremer J., Cush J., Schulze-Koops H., Connell C.A., Bradley J.D., Gruben D., Wallenstein G.V., Zwillich S.H., Kanik K.S. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N. Engl. J. Med. 2012, 367(6):495-507. ORAL solo investigators.
7. Ghoreschi K., Laurence A., O'Shea J.J. Selectivity and therapeutic inhibition of kinases: to be or not to be?. Nat. Immunol. 2009, 10(4):356-360.
8. Ghoreschi K., Jesson M.I., Li X., Ghosh S., Alsup J.W., Warner J.D., Tanaka M., Steward-Tharp S.M., Gadina M., Thomas C.J., Minnerly J.C., Storer C.E., LaBranche T.P., Radi Z.A., Dowty M.E., Head R.D., Meyer D.M., Kishore N., O'Shea J.J. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J. Immunol. 2011, 186(7):4234-4243.
9. Harris J.E., Fernandez-Vilaseca M., Elkington P.T., Horncastle D.E., Graeber M.B., Friedland J.S. IFNgamma synergizes with IL-1beta to up-regulate MMP-9 secretion in a cellular model of central nervous system tuberculosis. Faseb. J. 2007, 21(2):356-365.
10. Huang J.F., Yafawi R., Zhang M., McDowell M., Rittenhouse K.D., Sace F., Liew S.H., Cooper S.R., Pickering E.H. Immunomodulatory effect of the topical ophthalmic janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease. Ophthalmology 2012, 119(7):e43-50.
11. Indik Z.K., Hunter S., Huang M.M., Pan X.Q., Chien P., Kelly C., Levinson A.I., Kimberly R.P., Schreiber A.D. The high affinity Fc gamma receptor (CD64) induces phagocytosis in the absence of its cytoplasmic domain: the gamma subunit of Fc gamma RIIIA imparts phagocytic function to Fc gamma RI. Exp. Hematol. 1994, 22(7):599-606.
12. Kremer J.M., Bloom B.J., Breedveld F.C., Coombs J.H., Fletcher M.P., Gruben D., Krishnaswami S., Burgos-Vargas R., Wilkinson B., Zerbini C.A., Zwillich S.H. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase II a trial of three dosage levels of CP-690,550 versus placebo. Arthritis. Rheum. 2009, 60(7):1895-1905.
13. Lee S., Zheng M., Kim B., Rouse B.T. Role of matrix metalloproteinase-9 in angiogenesis caused by ocular infection with herpes simplex virus. J. Clin. Invest 2002, 110(8):1105-1111.
14. Liew S.H., Nichols K.K., Klamerus K.J., Li J.Z., Zhang M., Foulks G.N. Tofacitinib (CP-690,550), a janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial. Ophthalmology 2012, 119(7):1328-1335.
15. Ma Z., Qin H., Benveniste E.N. Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-gamma and IFN-beta: critical role of STAT-1alpha. J. Immunol. 2001, 167(9):5150-5159.
16. Mócsai A., Kovács L., Gergely P. What is the future of targeted therapy in rheumatology: biologics or small molecules?. BMC Med. Mar. 2014, 13(12):43.
17. Murray P.J. The JAK-STAT signaling pathway: input and output integration. J. Immunol. 2007, 178(5):2623-2629.
18. Okiyama N., Furumoto Y., Villarroel V.A., Linton J.T., Tsai W.L., Gutermuth J., Ghoreschi K., Gadina M., O'Shea J.J., Katz S.I. Reversal of CD8 T-cell-mediated mucocutaneous graft-versus-host-like disease by the JAK inhibitor tofacitinib. J. Invest. Dermatol 2014, 134(4):992-1000.
19. Paniagua R., Si M.S., Flores M.G., Rousvoal G., Zhang S., Aalami O., Campbell A., Changelian P.S., Reitz B.A., Borie D.C. Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts. Transplantation 2005, 80(9):1283-1292.
20. Papp K.A., Menter A., Strober B., Langley R.G., Buonanno M., Wolk R., Gupta P., Krishnaswami S., Tan H., Harness J.A. Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study. Br. J. Dermatol 2012, 167(3):668-677.
21. Saika S., Ikeda K., Yamanaka O., Miyamoto T., Ohnishi Y., Sato M., Muragaki Y., Ooshima A., Nakajima Y., Kao W.W., Flanders K.C., Roberts A.B. Expression of smad7 in mouse eyes accelerates healing of corneal tissue after exposure to alkali. Am. J. Pathol. 2005, 166(5):1405-1418.
22. Sakimoto T., Yamada A., Kanno H., Sawa M. Upregulation of tumor necrosis factor receptor 1 and TNF-alpha converting enzyme during corneal wound healing. Jpn. J. Ophthalmol. 2008, 52(5):393-398.
23. Sakimoto T., Sugaya S., Ishimori A., Sawa M. Anti-inflammatory effect of IL-6 receptor blockade in corneal alkali burn. Exp. Eye. Res. 2012, 97(1):98-104.
24. Sakimoto T., Ohnishi T., Ishimori A. Simultaneous study of matrix metalloproteinases, proinflammatory cytokines, and soluble cytokine receptors in the tears of noninfectious corneal ulcer patients. Graefes. Arch. Clin. Exp. Ophthalmol. 2014, 252(9):1451-1456.
25. Springall R., Amezcua-Guerra L.M., Gonzalez-Pacheco H., Furuzawa-Carballeda J., Gomez-Garcia L., Marquez-Velasco R., Mejía-Domínguez A.M., Cossío-Aranda J., Martínez-Sánchez C., Bojalil R. Interferon-gamma increases the ratio of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 in peripheral monocytes from patients with coronary artery disease. PLoS One 2013, 8(8):e72291.
26. Stevenson W., Sadrai Z., Hua J., Kodati S., Huang J.F., Chauhan S.K., Dana R. Effects of topical janus kinase inhibition on ocular surface inflammation and immunity. Cornea 2014, 33(2):177-183.
27. Yarilina A., Xu K., Chan C., Ivashkiv L.B. Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors. Arthritis. Rheum. 2012, 64(12):3856-3866.